Page 37 - Research Network News Today

An extended lymphadenectomy – removal of additional lymph nodes beyond the extent of the standard procedure – in patients undergoing radical cystectomy (removal of bladder and nearby tissues) because of clinically localized muscle-invasive bladder cancer provides no patient benefit as measured by disease-free survival or overall survival times. It does, however, increase the risk of adverse events (side effects) and post-surgical death. These primary results from the phase 3 SWOG S1011 clini...

What’s the Difference Between SEO and PPC?

Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances in treatments and clinical trials, how access to cancer care affects outcomes, integrative medicine and more at the 2023 American Society of Clinical Oncology meeting.

A new clinical trial is testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.

Join Digital Accessibility Services (DAS) as we celebrate Global Accessibility Awareness Day (GAAD) with Jennison Asuncion, the co-creator of GAAD. The event will be live streamed, live captioned, and recorded.  Register to attend in-person or virtually  View a map and directions to Askwith Hall. Harvard ID required for in-person attendance. 

The discovery of a skeleton and medical tools sheds light on the relationship between doctors and metal artisans in antiquity.

Author A Public Lecture by Mr. Batilloi Warritay, Communication for Development Expert, on “Prioritizing Communication in an Environment of Change: The Way Forward” on the 32nd Anniversary of the Founding of the Institute of Public Administration and Management (IPAM), at The British Council Auditorium, Thursday 06 December, 2012 Mr. Chairman, distinguished ladies and

Sharing Of Money Has Come To Stay In Politics – NDCs Solomon Nkansah

ISCA has set aside SGD2m (US$1.5m) to fund its Artificial Intelligence for the Accountancy Industry (AI for AI) initiative.

The frontline combination of ribociclib and letrozole significantly prolonged overall survival over letrozole alone in a subset of patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy, according to data from an exploratory analysis of the phase 3 MONALEESA-2 trial.